» Articles » PMID: 35145420

Feasibility of Growth Factor Agent Therapy in Repairing Motor Injury

Overview
Journal Front Pharmacol
Date 2022 Feb 11
PMID 35145420
Authors
Affiliations
Soon will be listed here.
Abstract

Growth factors (GF), with the activity of stimulating cell growth, play a significant role in biology, medicine, and exercise physiology. In the process of exercise, human tissues are impacted, making cells suffer damage. Growth factor can accelerate the repair of damaged cells and regulate the synthesis of protein, so biological preparations of growth factors can be added to traditional therapies. A combination of growth factor biologics and conventional therapies may improve the efficiency of injury repair, but growth factor biologics may not produce any results. The feasibility of growth factor biologics in the treatment of motor injury was discussed. The research have shown that: 1) GF biological agent therapy is a very promising treatment for motor injury, which is based on the power of autologous growth factor (GFs) to accelerate tissue healing, promote muscle regeneration, increase angiogenesis, reduce fibrosis, and make the muscle injury rapid recovery. 2) There are various methods for delivering the higher dose of GF to the injured tissue, but most of them depend on the platelet release of GF. At the site of injury, there are several ways to deliver higher doses of GF to the injured tissue. 3) At present, the inhibition of GF is mainly through signal transduction inhibitors and inhibition of transcription factor production. 4) Pattern of GF during wound repair: GF directly regulates many key steps of normal wound repair, including inflammatory cell chemotaxis, division and proliferation of fibroblasts, keratinocytes and vascular endothelial cells, formation of new blood vessels, and synthesis and degradation of intercellular substances. 5) When GF promotes chronic wound healing, in most cases, certain GF can be used targeted only when regulation still cannot meet the need for repair.

Citing Articles

Application of SMILES-based molecular generative model in new drug design.

Kong W, Hu Y, Zhang J, Tan Q Front Pharmacol. 2022; 13:1046524.

PMID: 36313306 PMC: 9606214. DOI: 10.3389/fphar.2022.1046524.


Characterization and Expression Analysis of Mollusk-like Growth Factor: A Secreted Protein Involved in Pacific Abalone Embryonic and Larval Development.

Hanif M, Hossen S, Cho Y, Sukhan Z, Choi C, Kho K Biology (Basel). 2022; 11(10).

PMID: 36290349 PMC: 9598359. DOI: 10.3390/biology11101445.

References
1.
Wu H, Sun Y, Wong W, Cui J, Li J, You X . The development of a novel transforming growth factor-β (TGF-β) inhibitor that disrupts ligand-receptor interactions. Eur J Med Chem. 2020; 189:112042. DOI: 10.1016/j.ejmech.2020.112042. View

2.
Seijas R, Ares O, Cusco X, Alvarez P, Steinbacher G, Cugat R . Partial anterior cruciate ligament tears treated with intraligamentary plasma rich in growth factors. World J Orthop. 2014; 5(3):373-8. PMC: 4095032. DOI: 10.5312/wjo.v5.i3.373. View

3.
Bachl N, Derman W, Engebretsen L, Goldspink G, Kinzlbauer M, Tschan H . Therapeutic use of growth factors in the musculoskeletal system in sports-related injuries. J Sports Med Phys Fitness. 2010; 49(4):346-57. View

4.
Zhang J, Liu Z, Tang J, Li Y, You Q, Yang J . Fibroblast growth factor 2-induced human amniotic mesenchymal stem cells combined with autologous platelet rich plasma augmented tendon-to-bone healing. J Orthop Translat. 2020; 24:155-165. PMC: 7548348. DOI: 10.1016/j.jot.2020.01.003. View

5.
Laver L, Carmont M, McConkey M, Palmanovich E, Yaacobi E, Mann G . Plasma rich in growth factors (PRGF) as a treatment for high ankle sprain in elite athletes: a randomized control trial. Knee Surg Sports Traumatol Arthrosc. 2014; 23(11):3383-92. DOI: 10.1007/s00167-014-3119-x. View